Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 71610-030

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71610-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 250mg (71610 030 60)

Bottle Label 250mg (71610 030 60)
Label for Divalproex Sodium ER 250 mg film-coated extended-release tablets. The package contains 90 tablets. Manufactured by Mylan Pharmaceuticals, Morgantown, WV, and repackaged by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. Includes storage instructions and RX only designation. National Drug Code (NDC) 71610-030-60 is shown.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Divalproex Sodium Structural Formula (Image 03)

Divalproex Sodium Structural Formula (Image 03)
Chemical structure of divalproex sodium, showing the sodium salt form of valproic acid with branched alkyl groups and carboxylate functional groups in a polymeric representation.*
FDA Label Image

Figure 1: Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Image 04)

Figure 1: Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Image 04)
A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium Delayed-Release and placebo across a population of patients. The vertical axis shows % reduction in CPS rate from -100% (worsening) to 100% (improvement), and the horizontal axis indicates the percentage of patients from 0 to 100%. The solid line represents Divalproex Sodium Delayed-Release, and the dashed line represents placebo treatment.*
FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)
A line graph comparing the percentage reduction in CPS rate between High Dose and Low Dose Divalproex Sodium Delayed Release, plotted against the percentage of patients. The vertical axis shows % Reduction in CPS Rate from -100% to 100%, with annotations for Improvement and Worsening. The graph shows trends for both high and low dose treatments.*
FDA Label Image

Figure 3: Mean Reduction In 4-week Migraine Headache Rates (Image 06)

Figure 3: Mean Reduction In 4-week Migraine Headache Rates (Image 06)
A bar graph comparing Placebo and Divalproex Sodium Extended-Release Tablets. The y-axis represents a numerical scale from 0 to 1.2, with the placebo bar reaching 0.6 and the Divalproex Sodium bar reaching 1.2, marked with an asterisk indicating statistical significance (p=0.006). The x-axis categories are Placebo and Divalproex Sodium Extended-Release Tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.